Archive for CD3

A Phase 1 Study of NM32-2668 (Anti-ROR1/Anti-CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors

“A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also knownas MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA)Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer”

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer

A first-in-human Phase I, non-randomized, open-label, multi-center dose escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by repeated intravenous infusions in patients with malignant solid tumors expressing B7-H6